Brain Cancer Breakthrough as Cariprazine Shows Powerful Effects Against Glioblastoma
Nikhil Prasad Fact checked by:Thailand Medical News Team Jun 14, 2026 1 hour, 19 minutes ago
Medical News: Glioblastoma is one of the deadliest forms of brain cancer, with patients often facing a grim prognosis despite surgery, radiation, and chemotherapy. Now, scientists in China have uncovered promising evidence that an existing psychiatric drug, cariprazine, may have the potential to fight this aggressive cancer through a previously unknown mechanism.
Existing antipsychotic drug cariprazine shows remarkable ability to slow glioblastoma growth and trigger cancer cell death
in preclinical studies
Researchers from the School of Pharmaceutical Sciences at Southwest University in Chongqing, China, and the NMPA Key Laboratory for Quality Monitoring of Narcotic Drugs and Psychotropic Substances at the Chongqing Institute for Food and Drug Control, China, have found that cariprazine can significantly suppress glioblastoma growth in laboratory and animal studies. Their findings suggest that the drug could eventually be repurposed as a novel treatment for one of the most difficult cancers to manage.
A Brain-Penetrating Drug with Unexpected Cancer-Fighting Potential
Glioblastoma remains notoriously difficult to treat because cancer cells spread rapidly throughout the brain and develop resistance to existing therapies. Another major obstacle is the blood-brain barrier, a protective shield that prevents many drugs from reaching brain tissue.
Cariprazine is already approved as an antipsychotic medication and is widely used for psychiatric disorders. Importantly, it can readily cross the blood-brain barrier, making it an attractive candidate for drug repurposing. Previous studies had hinted at anticancer effects in several other cancers, but its impact on glioblastoma had never been investigated in depth.
The research team discovered that cariprazine dramatically reduced the growth of several glioblastoma cell lines. As drug concentrations increased, cancer cell survival steadily declined. Even more encouraging, normal brain astrocyte cells were far less affected, suggesting a degree of selectivity toward tumor cells.
Cancer Cells Forced into Self-Destruction
One of the most striking findings was the drug's ability to trigger apoptosis, the process of programmed cell death.
Glioblastoma cells exposed to cariprazine showed clear signs of cellular damage and death. The treatment increased levels of proteins that promote apoptosis, including BAX and PARP, while reducing levels of BCL2, a protein that normally helps cancer cells survive.
The researchers also found evidence that the drug disrupted mitochondrial function inside cancer cells, an important step that often precedes cell death. Flow cytometry analyses confirmed that significantly more tumor cells entered late-stage apoptosis after treatment.
These results indicate that cariprazine does not merely slow tumor growth but actively pushes glioblastoma cells toward destruction.
Blocking Tumor Spread
Glioblastoma's deadly nature is partly due to its ability to invade surrounding brain tissue. Laboratory wound-he
aling and migration experiments showed that cariprazine significantly reduced the ability of glioblastoma cells to move and spread.
Cells treated with the drug demonstrated markedly lower migration rates compared to untreated cells, suggesting that cariprazine may help limit the invasive behavior that makes glioblastoma so difficult to eradicate.
Success in Animal Studies
The investigators then moved beyond laboratory dishes and tested the drug in mice implanted with glioblastoma tumors.
After two weeks of treatment, tumors in cariprazine-treated mice were substantially smaller than those in untreated animals. Importantly, the mice maintained stable body weight throughout the study, and examinations of liver and kidney tissues revealed no obvious signs of toxicity.
This combination of strong anticancer activity and apparent safety is particularly significant because many cancer drugs produce severe side effects that limit their clinical usefulness.
A Newly Identified Molecular Target
Perhaps the most groundbreaking aspect of the study was the discovery of how cariprazine works.
The researchers found that glioblastoma cells express unusually high levels of dopamine D2 and D3 receptors. Activation of these receptors promoted tumor growth, while cariprazine effectively blocked their cancer-supporting activity.
Further investigation revealed a key role for a protein known as beta-arrestin 2, or ARRB2. Cariprazine disrupted interactions between D2/D3 receptors and ARRB2, shutting down growth-promoting ERK signaling pathways inside tumor cells.
Unexpectedly, the drug also increased overall ARRB2 levels. When scientists artificially increased ARRB2 expression, glioblastoma growth slowed even further.
Conversely, reducing ARRB2 weakened the anticancer effects of cariprazine.
This
Medical News report highlights what may be the most important discovery of the study: ARRB2 appears to act as a central control point through which cariprazine exerts much of its tumor-suppressing activity.
Direct Binding Adds Another Layer of Action
Using molecular docking studies and protein-binding experiments, the scientists confirmed that cariprazine physically binds to ARRB2 itself.
Two specific amino acid sites, known as Leu245 and Phe246, were identified as critical binding locations. Mutating these sites significantly reduced the drug's ability to suppress tumor growth, providing strong evidence that direct interaction with ARRB2 contributes to its anticancer effects.
Conclusions
The findings present compelling evidence that cariprazine may represent a promising new weapon against glioblastoma. Unlike many experimental cancer drugs, cariprazine already has an established clinical safety profile and possesses the crucial ability to cross the blood-brain barrier. The study demonstrated that it can slow tumor growth, trigger cancer cell death, reduce migration, and suppress tumor development in animal models while causing minimal apparent toxicity. Equally important, the researchers uncovered a unique dual mechanism involving dopamine D2/D3 receptors and the ARRB2 signaling network. Although clinical trials will still be needed before any treatment recommendations can be made, these results provide a strong scientific foundation for exploring cariprazine as a repurposed therapy for one of the world's most aggressive and treatment-resistant brain cancers.
The study findings were published in the peer reviewed journal: Pharmaceuticals.
https://www.mdpi.com/1424-8247/19/6/928
For the latest on glioblastoma, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/articles/cancer
Share
Tweet
Share
